Learning Objectives

Metabolic Abnormalities Associated With T2D

CV Events With PPAR-gamma Agonists

Effect of Fibrates on CV Outcomes A Systematic Review and Meta-analysis

ACCORD Lipid Hazard Ratios for the Primary Outcome

Pioglitazone Meta-analysis Heart Failure & MI

Dual PPAR a/g Agonists

AleCardio Aleglitazar (PPAR a/g Agonist) in Patients With T2D and ACS

AleCardio Efficacy and Safety Outcomes

AleCardio Glycemic Control and Lipoprotein Effects

Genes Regulated by Glitazones

Older Antidiabetic Drugs and CV Benefit/Harm

SAVOR-TIMI 53 Clinical End Points: Saxagliptin (DPP4 Inhibitor) vs Placebo

SAVOR-TIMI 53 Hospitalization for Heart Failure Stratified by NT-proBNP Quartiles

SAVOR-TIMI 53 Safety Endpoints

EXAMINE Safety End Points: Alogliptin (DPP4 Inhibitor) vs Placebo

EXAMINE Heart Failure Outcomes

Mechanism of Heart Failure

Ongoing CVD Outcomes Trials in Type 2 Diabetes

Clinical Trial Design Considerations

AlePrevent Aleglitazar in Patients With Stable CVD and Glucose Abnormalities

Newer Antidiabetic Drugs & CV Risk Reduction

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)